CRACR2A

Across TCGA pan-cancer cohorts, CRACR2A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CRACR2A data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CRACR2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRACR2A expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where CRACR2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.608	0.949	.003	22	view →
CCRCC	OS	Quartile	All	0.540	1.000	.006	18	view →
PDAC	DFS	Tertile	IV	0.550	0.217	.024	4	view →
HNSC	DFS	Median	IV	0.801	0.575	.024	3	view →
UCEC	DFS	Median	All	0.935	0.764	.008	2	view →
LUAD	DFS	Quartile	All	0.839	0.989	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CRACR2A–LSCC (DFS)

Open the LSCC breakdown →